The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1445
June 23, 2014
View Complete Issue         Table of Contents 2019 
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
June 23, 2014 (Issue: 1445)
The FDA has approved another solution of the aminoglycoside antibiotic tobramycin (Bethkis – Chiesi/Cornerstone) for oral inhalation via a nebulizer for management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
Article code: 1445c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.